-
Views
-
Cite
Cite
Jasvinder A Singh, Larry R Hearld, Seth Eisen, W Winn Chatham, Sonali Narain, Narender Annapureddy, Diane L Kamen, Kimberly Trotter, Vikas Majithia, Cathy Lee Ching, Zineb Aouhab, Swamy Venuturupalli, Daniel J Wallace, Rosalind Ramsey-Goldman, Alfred Kim, Maureen McMahon, S Sam Lim, Kalpana Bhairavarasu, Alexa Meara, Kenneth Kalunian, Mark Beasley, for the Implementing DEcision-Aid for Lupus in clinics (IDEAL) Consortium , Implementation outcomes of a patient decision-aid in a diverse population with systemic lupus erythematosus in 15 U.S. rheumatology clinics, Rheumatology, 2025;, keaf205, https://doi.org/10.1093/rheumatology/keaf205
- Share Icon Share
Abstract
To examine the clinic outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus.
We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019–2024 (including the COVID-pandemic). We collected Organizational Readiness to Implement Change (ORIC), and Team Learning and Psychological Safety Survey (TLPSS) at baseline. The primary study outcome objective measure was penetration/reach at the end-of-study (=enrolled*100/eligible SLE patients). We used validated clinic personnel surveys to examine perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4-, 12- and 24-months post-PtDA implementation.
Clinic personnels’ (n = 184) baseline ORIC commitment and efficacy scores (a 0–5 scale, higher=better) ranged from 3.5–4.2, and 3.4–4.4 for the sites, respectively; TLPSS scores (a 0–7 scale, higher=better) were 3.9–5.5 for internal learning, 3.7–5.6 for external learning, and 4.3–5.5 for psychological safety. Penetration (primary outcome) among 15 geographically diverse U.S. rheumatology clinics ranged 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinic personnel perceived lupus PtDA outcomes were optimal at 4-months (all scale score ranged 1–5, higher=better): (1) appropriateness, 3.43 (SD, 0.86); (2) acceptability, 3.53 (SD, 0.83); (3) feasibility, 3.44 (SD, 0.71); (4) success, 3.41 (SD, 0.73); and (5) permanence, 3.22 (SD, 0.74).
We implemented a lupus PtDA with varied success rates during the COVID-pandemic; more providers were associated with higher clinic penetration. Clinic personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24-months.
ClinicalTrials.gov, NCT03735238
Comments